June 3, 2026
PharmaBoardroom Interviews Thomas Madden – CEO, Acuitas Therapeutics
In this interview, Madden shares how the company is evolving beyond COVID. He discusses the company’s preformed vesicle technology and its potential to make personalized genetic medicines shelf-ready, the clinical and infrastructure challenges facing n-of-1 therapies, and his view of where LNP technology is headed over the next five years.
“The most pressing question is: how do we make this technology doctor-friendly, pharmacist-friendly, patient-friendly, and bring the cost down so that it is accessible?”